Can we make clinical trials more diverse?
The US FDA are hoping to lead the way in addressing the lack of diversity and representation in clinical trials when developing medicines through new legislation.
As part of a recent bill passed into law by President Biden, the US FDA will necessitate diversity in participants in late-stage clinical trials.
It has been widely recognised that there is a lack of diversity in clinical trials, something that is key to ensuring the medicine on trial is tested comprehensively, to make sure that it is effective in different patient populations. Even though this was known, there hasn’t been any regulation to mitigate the problem and ensure diversity in trials.
Now, since a report from the US National Academies of Sciences, Engineering and Medicine was published in 2022 on building research equity for women and underrepresented groups, a shift in legislation has been encouraged. The report found that there was a significant lack of representation in clinical trials across North America, which gave rise to a number of consequences.
These include incurring an extra cost of potentially hundreds of billions of dollars across the healthcare industry, curbs innovation and new discoveries, exacerbates the lack of accessibility to effective medicines, and leads to a lack of trust from patients in the medical establishment, among others.
This isn’t to say there hasn‘t been an improvement in recent years, between 2012 and 2017 79% of clinical trials in the US used in decision making by the FDA achieved a good level of representation for women; however, this statistic is marred by the fact that 27% of trials adequately represented older adults, and even more disheartening, only 11% achieved a reasonable threshold for participants of minority racial and ethnic origin. This also highlights that the statistic for women largely implies the inclusion of women of white decent.
To fulfil the new guidelines, researchers and pharmaceutical companies designing clinical trials will have to submit a plan for how they intend to incorporate more diverse participation in their trial. This will mean that these parties have to address structural and systemic problems that are the root cause of the current lack of diversity. Of course this can only mean progress, by making medical provision and trial sites more accessible and by working to build trust in these under-represented communities, which have so often been mistreated in the past.
Jennifer Miller, a bioethicist at Yale School of Medicine (CT, USA), stated:
“This is the first time we’re going to have companies proactively plan enrolment targets and submit them to regulators.”
Enforcing the regulations won’t be without it’s challenges, but it is a significant step towards rectifying the disparities in clinical trial recruitment and developing better medicines, and will hopefully inspire other regulators in different countries to put in place similar measures.
Related News
-
News More to celebrate at the CPHI Milan Pharma Awards 2024
The CPHI Milan Pharma Awards, which are now open for nominations until 18 May 2024, celebrate the innovators making a difference. This year, two new categories have been added to further honour the contributions of a diverse range of pharma professiona... -
News Special Edition Women in Pharma: Women’s health and the pharmaceutical industry
International Women’s Day is an annual celebration of women around the world every March 8. March also marks Women’s History Month. This March, our Women in Pharma series takes a look at how women’s healthcare has developed, and the r... -
News Informa Markets International Women’s Day Panel Discussion
On March 7, 2024, the Informa Markets Amsterdam office hosted an International Women’s Day Breakfast and Panel Discussion to celebrate the women who drive the B2B events industry forward, including members of the CPHI team. -
News 5 African American Pharmaceutical Pioneers: Honouring Black History Month
In recognition of February as Black History Month in the United States, we cover the lives and works of five pioneering African American pharmaceutical professionals who have contributed significantly to the world of pharmaceuticals and drug devel... -
News Genome study discovers 275 million new variants across a diverse population
A new genome study undertaken in the US, accounting for a diverse range of people, has led to the discovery of nearly 300 million new genetic variants, which could inform markers of disease. -
News Special Edition Women in Pharma: International Day of Women and Girls in Science
In this monthly series, we bring insightful content, events, and communities dedicated to sharing best practices for DE&I strategies and showcasing underrepresented voices in the pharmaceutical community. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance